IP Waiver Proposal Won’t Hold Back Moderna’s Rise
Bancel: 'IP Is Not The Issue'
Executive Summary
While White House support for an intellectual property waiver has been cheered by access campaigners, Moderna said it won’t help solve the pandemic’s big vaccine production challenges any time soon.
You may also be interested in...
Flagship's $3.37bn Fund To Grow First-In-Category Firms
Flagship, the investor behind COVID-19 success story Moderna, has raised a huge fund that will be used to create and develop its own companies before spinning them off.
As COVID-19 Vaccine Sales Surge, BioNTech Pledges 40% Will Go To Poorer Nations
Angela Merkel consulted company’s CEO before opposing IP waiver, backing the future of Germany’s new ‘big biotech’ company.
IP Waiver Might Kick-Start China's Novel COVID-19 Vaccine Effort
As the US responds to calls to waive intellectual property rights related to COVID-19 vaccines, China is already moving ahead with some of its own mRNA candidates.